Table 2. Characteristics of the patients with osteoarthritis (OA).
| Sex | Age (yr) | Duration of illness (yr) | Peripheral leukocyte counts (/mm3) | Serum CRP level (mg/dL) | Serum anti-CCP Ab level (U/mL) | Serum MMP3 level (ng/mL) | Serum RF level (mg/dL) | Medication | |
|---|---|---|---|---|---|---|---|---|---|
| OA1 | F | 88 | 1 | 3,500 | 0.1 | ND | ND | ND | NSAIDb) |
| OA2 | F | 69 | 27 | 3,200 | 0.11 | ND | ND | ND | APAP |
| OA3 | M | 58 | 2 | 5,000 | 0.23 | ND | ND | ND | NSAIDa) |
| OA4 | M | 53 | 1 | 4,600 | 0.1 | ND | ND | ND | NSAIDa) |
| OA5 | F | 85 | 3 | 5,600 | 0.1 | ND | ND | ND | NSAIDa) |
| OA6 | F | 80 | 6 | 7,600 | 0.21 | ND | ND | ND | NSAIDb) |
| OA7 | M | 75 | 6 | 6,900 | 0.1 | ND | ND | ND | APAP |
| OA8 | M | 69 | 10 | 5,200 | 0.15 | ND | ND | ND | NSAIDa) |
| OA9 | M | 77 | 10 | 6,100 | 0.1 | ND | ND | ND | APAP |
| OA10 | M | 84 | 1 | 6,500 | 0.1 | ND | ND | ND | NSAIDb) |
| OA11 | F | 67 | 10 | 7,000 | 0.1 | ND | ND | ND | NSAIDa) |
| OA12 | M | 75 | 6 | 5,100 | 0.1 | ND | ND | ND | NSAIDb) |
| OA13 | M | 65 | 2 | 4,300 | 0.1 | ND | ND | ND | NSAIDa) |
| OA14 | F | 67 | 8 | 4,800 | 0.14 | ND | ND | ND | NSAIDb) |
| OA15 | F | 85 | 20 | 3,800 | 0.1 | ND | ND | ND | NSAIDb) |
| OA16 | F | 73 | 10 | 4,900 | 0.1 | ND | ND | ND | APAP |
| OA17 | F | 74 | 2 | 5,600 | 0.1 | ND | ND | ND | NSAIDb) |
| OA18 | M | 88 | 44 | 7,300 | 0.1 | ND | ND | ND | APAP |
| OA19 | F | 86 | 29 | 6,100 | 0.14 | ND | ND | ND | APAP |
| OA20 | M | 80 | 3 | 6,200 | 0.89 | ND | ND | ND | NSAIDb) |
| OA21 | F | 76 | 4 | 6,600 | 0.1 | ND | ND | ND | NSAIDb) |
| OA22 | M | 80 | 2 | 3,200 | 0.1 | ND | ND | ND | NSAIDb) |
| OA23 | F | 83 | 7 | 7,800 | 0.37 | ND | ND | ND | NSAIDb) |
| OA24 | F | 81 | 31 | 5,100 | 0.1 | ND | ND | ND | APAP |
| OA25 | M | 75 | 8 | 4,400 | 0.11 | ND | ND | ND | APAP |
| OA26 | F | 72 | 9 | 7,000 | 2.2 | ND | ND | ND | NSAIDa) |
APAP, acetaminophen; anti-CCP Ab, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; MMP3, matrix metalloproteinase-3; ND, not done; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis; RF, rheumatoid factor.
a)Loxoprofen 180 mg/day. b)Celecoxib 200 mg/day.